Avi Livneh
- Nephrology top 0.2%
- Gout, Hyperuricemia, Uric Acid 33
- Immunology top 0.5%
- interferon and immune responses 35
- IL-33, ST2, and ILC Pathways 27
- Molecular Biology top 0.5%
- Inflammasome and immune disorders 147
- Amyloidosis: Diagnosis, Treatment, Outcomes 48
- Rheumatology top 0.5%
- Systemic Lupus Erythematosus Research 24
- Hematology top 1%
-
- Cholesterol and Lipid Metabolism 20
-
- Monoclonal and Polyclonal Antibodies Research 20
- Co-authors
- Pnina LangevitzMordechai PrasMerav LidarDeborah ZemerShai PadehNurit ZaksIlan Ben‐ZviYael Shinar
- Journals
- New England Journal of Medicine (1 paper)SHILAP Revista de lepidopterología (1 paper)The Journal of Immunology (5 papers)
- Partner nations
- IsraelUnited StatesItaly
In The Last Decade
Avi Livneh
258 papers receiving 8.7k citations
Hit Papers
Peers
Comparison fields: 5 of 118
- Nephrology 2.0k
- Immunology 3.6k
- Molecular Biology 7.0k
- Rheumatology 1.4k
- Hematology 1.0k
Countries citing papers authored by Avi Livneh
This map shows the geographic impact of Avi Livneh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Avi Livneh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Avi Livneh more than expected).
Fields of papers citing papers by Avi Livneh
This network shows the impact of papers produced by Avi Livneh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Avi Livneh. The network helps show where Avi Livneh may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Avi Livneh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 4 | |
| 2 | 2019 | 3 | |
| 3 | A high and equal prevalence of the Q703K variant in NLRP3 patients with autoinflammatory symptoms and ethnically matched controls. | 2018 | 5 |
| 4 | 2018 | 26 | |
| 5 | 2017 | 10 | |
| 6 | Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial. | 2014 | 18 |
| 7 | Risk factors for amyloidosis and impact of kidney transplantation on the course of familial Mediterranean fever. | 2012 | 11 |
| 8 | The Israeli Annual FMF, Amyloidosis and Other Autoinflammatory Diseases Meeting (July 2011): a bridge spanning these entities. | 2012 | 1 |
| 9 | 2012 | 22 | |
| 10 | 2010 | 13 | |
| 11 | 2010 | 44 | |
| 12 | 2009 | 4 | |
| 13 | 2005 | 105 | |
| 14 | 2005 | 68 | |
| 15 | 2001 | 13 | |
| 16 | 1997 | 98 | |
| 17 | 1996 | 27 | |
| 18 | 1995 | 9 | |
| 19 | [Atrial septal aneurysm and paroxysmal atrial fibrillation]. | 1994 | 1 |
| 20 | 1988 | 2 |
About Avi Livneh
Avi Livneh is a scholar working on Nephrology, Immunology and Rheumatology, having authored 263 papers that have together received 9.0k indexed citations. Recurring topics across this work include Inflammasome and immune disorders (147 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (48 papers), interferon and immune responses (35 papers), Gout, Hyperuricemia, Uric Acid (33 papers), IL-33, ST2, and ILC Pathways (27 papers), Systemic Lupus Erythematosus Research (24 papers), Cholesterol and Lipid Metabolism (20 papers) and Monoclonal and Polyclonal Antibodies Research (20 papers). The work is most often cited by research in Nephrology (2.0k citations), Immunology (3.6k citations) and Molecular Biology (7.0k citations). Avi Livneh has collaborated with scholars based in Israel, United States and Italy. Frequent co-authors include Pnina Langevitz, Mordechai Pras, Merav Lidar, Deborah Zemer, Shai Padeh, Nurit Zaks, Ilan Ben‐Zvi, Yael Shinar, A Migdal and Salim Kees. Their work appears in journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.